By Michael Wong, JD (Founder & Executive Director, Physician-Patient Alliance for Health & Safety)
This is the question that I recently asked myself – “Has WellCare Put Profits Before Patients?”
In a letter to Ken Yamaguchi, MD, MBA (Executive Vice President, Chief Medical Officer WellCare Prescription Insurance, Inc.), the Partnership to Advance Cardiovascular Health (together with a coalition of concerned organizations, including the Physician-Patient Alliance for Health & Safety) ask Dr. Yamaguchi about a pricing decision WellCare made for seniors that will increase the price of a drug by five times what they had previously paid:
recent formulary change that will drastically increase the price of apixaban for Medicare Part D WellCare participants. By placing apixaban on a higher formulary tier, medically fragile seniors will pay five times as much for their life-saving direct oral anticoagulant (DOAC).